Search
Displaying 561–570 of 714 for “retinal diseases”
-
Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis
Research NewsData monitoring committee recommends proceeding with registration-enabling study for ATSN-201
-
MeiraGTx Acquires XLRP Gene Therapy Bota-Vec, Moves Toward Regulatory Filing
Research NewsMeiraGTx has acquired bota-vec, a gene therapy for X-linked retinitis pigmentosa (XLRP), and plans to file for regulatory approval in the U.S., Europe, and Japan, with a potential launch in 2027.
-
Leber Congenital Amaurosis Research Advances
Research NewsRecent developments in research on Leber congenital amaurosis.
-
Films & Documentaries Showcase
Celebrating the powerful stories of individuals in the blind and low vision community through the art of film.
-
About Page
The Foundation Fighting Blindness Brand Ambassador Program empowers passionate individuals affected by blinding diseases to share their stories, raise awareness, and inspire action in the fight against vision loss. Together, we’re amplifying voices and accelerating our path to treatments and cures.
-
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
Research NewsThe therapy delivers copies of the RORA gene to address multiple disease pathways.
-
Want to support this historic event? Sponsorship and exhibitor opportunities are available for organizations, foundations, and industry partners dedicated to advancing retinal research and innovation. Learn more by sending an email to Partnerships@FightingBlindness.org.
-
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
Eye on the CureDr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
Mental Health Advisory Council
The Foundation Fighting Blindness mental health initiative is guided by a mental health advisory council (MHAC) which includes five expert therapists (four of whom are blind or have low vision), a retinal specialist who has treated patients facing severe depression and anxiety, and a Foundation Board Member affected by vision loss who organized a local mental health support group.
.png)
